Edward W Mcguire

US Patent:

20050032742, Feb 10, 2005

Filed:

Aug 1, 2002

Appl. No.:

10/485892

Inventors:

Shawn DeFrees - North Wales PA, US
Edward McGuire - Furlong PA, US

International Classification:

A61K031/739
C08B037/00
C12P019/26

US Classification:

514054000, 435084000, 536053000

Abstract:

In vitro/cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel compounds that comprise sphingoid groups are disclosed. The compounds include sialylated oligosaccharides including gangliosides as well as various sphingoids and ceramides.

US Patent:

60967250, Aug 1, 2000

Filed:

Jul 2, 1997

Appl. No.:

8/887270

Inventors:

Paul M. Simon - Wilmington DE
Edward J. McGuire - Furlong PA

Assignee:

Neose Technologies, Inc. - Horsham PA

International Classification:

A61K 3170

US Classification:

514 53

Abstract:

The invention relates to methods for attenuating xenograft rejection in humans and old world monkeys, using oligosaccharides containing a Gal. alpha. 1-3Gal motif, to neutralize or remove anti-. alpha. Gal antibodies. The invention additionally relates to methods for site directed activation of the complement cascade or host leukocytes using oligosaccharides containing a Gal. alpha. 1-3Gal motif to target anti-. alpha. Gal antibodies. The invention further relates to pharmaceutical compositions that may be used in the practice of the invention. Such compositions contain, as the active ingredient, an oligosaccharide containing a Gal. alpha. 1-3Gal motif effective in binding anti-. alpha. Gal antibodies in vivo or ex vivo.

US Patent:

57536309, May 19, 1998

Filed:

Feb 8, 1996

Appl. No.:

8/598431

Inventors:

David A. Zopf - Strafford PA
Paul M. Simon - Wilmington DE
Stephen Roth - Gladwyne PA
Edward J. McGuire - Furlong PA
Dennis H. Langer - Princeton NJ

Assignee:

Neose Technologies, Inc. - Horsham PA

International Classification:

A61K 3170
C07H 1500

US Classification:

514 25

Abstract:

A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I (NeuAc-. alpha. (2-3)-pGal-. beta. (1)--(--X--). sub. m --(--Y--). sub. n --). sub. p --Z wherein X=a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z; wherein the C. sub. 1 glycosidic oxygen of galactose may be replaced by N, S or C; Y=a linking group; Z=a multivalent support; m=0 or 1; n=0 or 1; and p=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula II NeuAc-. alpha. (214 3)-pGal-. beta. (1)-A wherein A=a group capable of bonding to the p galactose; wherein the C. sub.

US Patent:

58830790, Mar 16, 1999

Filed:

May 12, 1998

Appl. No.:

/075862

Inventors:

David A Zopf - Strafford PA
Paul M. Simon - Wilmington DE
Stephen Roth - Gladwyne PA
Edward J. McGuire - Furlong PA
Dennis H. Langer - Princeton NJ

Assignee:

Neose Technologies, Inc. - Horsham PA

International Classification:

A61K 31715
A61K 3173

US Classification:

514 25

Abstract:

A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I (NeuAc-. alpha. (2-3)-pGal-. beta. (1)-(--X--). sub. m --(--Y--). sub. n -). sub. p -Z wherein X=a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z; wherein the C. sub. 1 glycosidic oxygen of galactose may be replaced by N, S or C; Y=a linking group; Z=a multivalent support; m=0 or 1; n=0 or 1; and p=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula II NeuAc-. alpha. (2-3)-pGal-. beta. (1)-A wherein A=a group capable of bonding to the p galactose; wherein the C. sub.

US Patent:

56209649, Apr 15, 1997

Filed:

Jun 5, 1995

Appl. No.:

8/461000

Inventors:

Stephen Roth - Gladwyne PA
Edward J. McGuire - Furlong PA
Dennis H. Langer - Princeton NJ

Assignee:

Neose Technologies, Inc. - Horsham PA

International Classification:

A61K 31715

US Classification:

514 53

Abstract:

A composition for treating and/or inhibiting gastric and duodenal ulcers, comprising an oligosaccharide selected from the group consisting of Formula I ##STR1## or a mixture thereof; wherein: X is independently OH or NHAc; Y is independently H, or an amino acid or a peptide of 2-100, preferably 2-20, amino acids; and W, W', and W" are each independently H or ##STR2## where Z is independently H or a pharmaceutically acceptable cation; and P is independently H or ##STR3## where Z is defined as above; wherein at least one of W, W' or W" is an. alpha. -N-acetylneuraminic acid moiety, and wherein W' and W" are not simultaneously. alpha. -N-acetylneuraminic acid moiety with the proviso that the compound of Formula II is not NAN. alpha. (2. fwdarw. 3)Gal. beta. 1-4 Glu or NAN. alpha. (2. fwdarw. 6)Gal. beta. 1-4 Glu; and a kit for detecting the presence of Helicobacter pylori comprising at least one compound of the Formula I or II, are described.

US Patent:

55146600, May 7, 1996

Filed:

Jun 7, 1995

Appl. No.:

8/474199

Inventors:

David A. Zopf - Strafford PA
Paul M. Simon - Wilmington DE
Stephen Roth - Gladwyne PA
Edward J. McGuire - Furlong PA
Dennis H. Langer - Princeton NJ

Assignee:

NEOSE Pharmaceuticals, Inc. - Horsham PA

International Classification:

A61K 31715
A61K 3173

US Classification:

514 25

Abstract:

A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I (NeuAc-. alpha. (2-3)-Gal-. beta. (1)-(--X--). sub. m -(--Y--). sub. n -). sub. p -Z wherein X=a chemical bond or a group capable of linking the galactose to either the linking group Y or the multivalent support Z; wherein the C. sub. 1 glycosidic oxygen of galactose may be replaced by N, S or C; Y=a linking group; Z=a multivalent support; m=0 or 1; n=0 or 1; and p=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula II NeuAc-. alpha. (2-3)-Gal-. beta. (1)-A wherein A=a group capable of bonding to the galactose; wherein the C. sub.